DNDaijing Nie

Daijing Nie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daijing Nie has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Hongxing Liu

    Precision Medicine Center, Beijing Lu Daopei Institute of Hematology, Beijing, China; Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China; Division of Pathology and Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing.

    14 shared publications
  • Fang Wang

    Division of Pathology & Laboratory Medicine Hebei Yanda Lu Daopei Hospital Langfang China

    11 shared publications
  • Lili Liu

    Hebei Yanda Lu Daopei Hospital

    10 shared publications
  • Panxiang Cao

    Division of Pathology & Laboratory Medicine Hebei Yanda Lu Daopei Hospital Langfang China

    10 shared publications
  • Yang Zhang

    Division of Pathology & Laboratory Medicine Hebei Yanda Lu Daopei Hospital Langfang China

    10 shared publications
  • Jing Zhang

    Division of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

    9 shared publications

Latest Publications

  • Open Access

    Genetic Factors and the Outcomes of Transplant-Associated Thrombotic Microangiopathies

    by Daijing Nie, Lili Liu

    Transplant-associated thrombotic microangiopathy (TA–TMA) is a severe endothelial complication following allogeneic hematopoietic stem-cell transplantation (allo-HSCT), associated with high mortality when not promptly diagnosed and treated. This study aimed to delineate the genetic landscape associated with TA–TMA and assess its impact on clinical outcomes. We retrospectively analyzed 1069 allo-HSCT recipients between January 2016 and May 2020, identifying 131 patients who met diagnostic criteria for TA–TMA (incidence rate: 12.25%). Genomic DNA sequencing was performed targeting 17 complement- related genes, identifying 74 genetic variants in 58 TA–TMA patients, including seven large deletions within the CFH–CFHR5 locus. Survival analysis indicated significantly poorer outcomes for TA–TMA patients compared to non-TMA patients (24.4% vs 62.4% survival at maximum follow-up, p = 0.025). However, cumulative incidence curves revealed no significant difference in TA–TMA onset between genetic variant carriers and non-carriers. These findings underscore the complexity of TA–TMA pathogenesis, suggesting that genetic predisposition alone is insufficient without additional endothelial insults. The limited predictive value of individual markers highlights the need for integrated biomarker strategies. Future research should focus on refining risk stratification models incorporating comprehensive genetic profiles, dynamic biomarkers, and longitudinal clinical parameters to enable earlier identification and targeted interventions, thereby improving post-transplant survival outcomes.

  • Open Access

    Inherited STAT3 mutation mediates familial autoimmune disease, leukemogenesis, and responses to immunomodulator

    by Daijing Nie, Qian Zhan

    Germline activating mutations in STAT 3 result in immune dysregulation, autoimmunity, and increased malignancy risk, yet the precise molecular mechanisms underlying disease heterogeneity remain unclear. We identified a familial germline STAT 3 p.R278H mutation shared between the parent diagnosed with T-cell large granular lymphocytic leukemia and the proband presenting with infantile-onset multisystem autoimmune disease-1. Employing whole-exome sequencing, single-cell RNA sequencing, comprehensive cytokine profiling, and flow cytometry-based immunophenotyping, we characterized their distinct clinical phenotypes and underlying immune dysregulation. Single-cell transcriptomics revealed marked expansion of CD8 + T cells in the proband, accompanied by altered expression of JAK/STAT pathway genes, including elevated STAT3, STAT 1 , and downstream target genes ( BATF, MAF, MYC ), but diminished cytokine transcripts ( IL1B, TNF ). Serum cytokines, however, were markedly elevated, highlighting discordant transcriptional and translational regulation. The parent exhibited additional somatic mutations, notably FLT 3 -ITD, suggesting a multi-hit model underpinning leukemogenesis rather than direct oncogenic transformation by STAT 3 alone. Immunomodulatory therapies, including cyclosporin A and tacrolimus, controlled autoimmune symptoms in the proband, whereas the parent was refractory to conventional treatments, ultimately succumbing after unsuccessful hematopoietic stem cell transplantation. Our findings emphasize that germline STAT 3 activating mutations predispose individuals to complex immune dysregulation and require additional somatic mutations to initiate overt malignancy. This study supports comprehensive genetic profiling and precision medicine approaches for patients harboring congenital STAT 3 mutations, aiming to optimize clinical management and improve therapeutic outcomes.

  • Open Access

    DNTT activation, TdT‐aided gene length mutation, and better prognosis in ATG‐based regimen allo‐HSCT in AML

    by Xiaosu Zhou, Daijing Nie, Yang Zhang, Zhixiu Liu, Yanli Zhao, Jianping Zhang, Fang Wang, Jiancheng Fang, Panxiang Cao, Xue Chen, et al.

    This study aimed to investigate the relationship between anomalous DNA nucleotidylexotransferase (DNTT) activation and the mutagenesis of gene length mutations (LMs) in acute myeloid leukemia (AML), and the relevance of their prognosis in antithymocyte globulin (ATG)‐based regimen allogeneic hematopoietic stem cell transplantation (allo‐HSCT). A cohort of 578 AML cases was enrolled. Next‐generation sequencing was performed to screen mutations of 86 leukemia driver genes. RNA‐seq was used to analyze gene expression. Prognostic analysis was investigated in 239 AML cases who underwent ATG‐based regimen allo‐HSCT. We report a refined subtyping algorithm of LMs (type I–IV) based on sequence anatomy considering the TdT‐aided mutagenesis mechanism. GC content adjacent to LM junctions, inserted nontemplate nucleotide bases, and DNTT expression analysis supported the DNTT activation and TdT‐aided mutagenesis in type II/III LMs in the total AML cohort. Both single‐variate and multivariate analyses showed a better overall survival of FLT3 type III compared to type I in a subset of ATG‐based regimen allo‐HSCT cases. The novel LM subtyping algorithm not only deciphers the etiology of the mutagenesis of LMs but also helps to fine‐tune prognosis differentiation in AML. The possible prognostic versatility of this novel LM subtyping algorithm in terms of chemotherapy, targeted therapy, and allo‐HSCT merits further investigation.


  • Targeted minor histocompatibility antigen typing to estimate graft-versus-host disease after allogeneic haematopoietic stem cell transplantation

    by Daijing Nie, Jing Zhang, Lili Liu, Xvxin Li, Jingyu Wang, Jianling Wang, Wei Zhang, Jiaqi Chen, Xiaosu Zhou, Yincheng Tan, et al.

    Graft-versus-host disease (GVHD) is a critical complication after allogeneic haematopoietic stem cell transplantation induced by genetic differences in donor–recipient pairs. Rigorous HLA matching has reduced GVHD, but severe GVHD still occurs. Minor histocompatibility antigens (mHAs) are another source of GVHD inducers. We designed a multi-mHA panel with 35 valid mHA loci and retrospectively analyzed 391 donor–recipient pairs with the anticipation of implementing mHA typing into clinical practice to optimize donor selection. Results showed the total mismatching in mHA loci in this panel, as well as mismatching in the GVH direction in unmatched-related recipients (UMRs) were 1.8 times and 1.3 times as those in matched-sibling recipients (MSRs) (p = 4.1e-4, p = 0.012, respectively). There was no significant association between mHA loci mismatching and grades II-IV acute GVHD (aGVHD), III-IV aGVHD, extensive chronic GVHD (cGVHD), or relapse in neither group. UMRs had an increased cumulative incidence of II-IV aGVHD (p = 0.002), but there was no statistical difference of the incidences in severe aGVHD or cGVHD (p = 0.093; p = 0.930). This is a preliminary study to explore GVHD risks brought by mHA loci mismatching in both unmatched-related recipients and matched-full-sibling recipients. Our results confirmed that stringent HLA matching is the key to reduce the risks for GVHD.


  • Identification of a novel AVEN‐NUTM1 fusion gene in acute myeloid leukemia

    by Lili Yuan, Xue Chen, Xingyu Cao, Fang Wang, Yang Zhang, Xiaoli Ma, Panxiang Cao, Jiancheng Fang, Jiaqi Chen, Xiaosu Zhou, et al.


  • Open Access

    NGS-Based Screening to Comprehensively Decipher TKIs Resistant Mutations in BCR-ABL1 Positive Leukemias

    by Hongxing Liu, Jiaqi Chen, Fang Wang, Jiancheng Fang, Wen Teng, Xue Chen, Yang Zhang, Xiaoli Ma, Panxiang Cao, Daijing Nie, et al.

    In BCR-ABL1 positive leukemia, mutations in the BCR-ABL1 kinase domain (KD) are the most common TKIs resistance mechanism. Sanger sequencing (SS) is currently the gold standard for detecting ABL1 KD mutations, but its low detection sensitivity cannot reveal mutations below 20% VAFs (variant allele frequency), and it is challenging to distinguish compound or polyclonal mutations. In recent years, the NGS-based BCR-ABL1 KD mutation screening protocol provides a powerful tool for deciphering complex patterns (compound or polyclonal mutations) and higher detection sensitivity (~2%, hotspot mutation 1%). Based on an inhouse designed NGS-based BCR-ABL1 KD mutation screening protocol, we retrospectively analyzed 348 specimens that undergone SS (ALL, n=164, CML, n=128, CML-BP, n=33, AML, n=3, other, n=20, other includes MAL, B-LBL). The BCR-ABL1 transcripts of 109 cases were 0, 184 cases were >0.1%, and the remaining 55 cases were between 0-0.1%. NGS screening results showed that the average VAF was 32.81% (range, 1.0%-100%), which was not provided by SS. Compared with SS, NGS screening provided a higher mutation-positive rate (22.13% vs. 33.05%, P =0.0013), and Gatekeeper T315I remained the most common BCR-ABL1 KD mutation (12.24% vs. 14.06%, P =0.4513). When the BCR-ABL1 transcript was 0, no mutation was detected in SS; while NGS ABL1-KD discovered mutations in 12 cases (0 vs. 11.01%, P =0.0004) with VAFs lower than 10% except for one S438F (VAF 14.9%) mutation,among them are the well-known F359V and E450G, as well as ten rare mutations, including T277A and E494K. There were also significant differences in mutations between 0 and 0.1% in BCR-ABL1 transcripts (16.36% vs 32.73%, P =0.046). However, when the BCR-ABL1 transcript >0.1%, there was no difference in mutation-positive rate between the two groups (36.96% vs. 46.20%, P=0.072). NGS screening disclosed more multiple mutations (59 vs 82, P =0.03), with significant advantages in detecting >3 mutations (3 vs 18, P = 0.0009). Compound mutations (CMs) were determined in 8 cases (8/384, 2.08%), with the incidence of 24.24% (8/33) in cases which carrying two or more mutations, of which T315I-including CMs were the most common (6/8, 75%). CMs or polyclonal mutation analysis is particularly crucial for severe patients who have received multiple consecutive TKIs treatments, and those with multiple background mutations and a higher risk of progression to clinical resistance. Our results showed that the inhouse designed NGS-based screening protocols could decipher TKIs resistant mutations more comprehensively than SS(Fig 1), and worthy of being implicated in clinical practice. Figure 1 Disclosures: No relevant conflicts of interest to declare.


  • Open Access

    Dynamic evolution of ponatinib‐resistant mutations in BCR–ABL1‐positive leukaemias revealed by next‐generation sequencing

    by Jiaqi Chen, Fang Wang, Jiancheng Fang, Daijing Nie, Yang Zhang, Xue Chen, Yu Li, Yincheng Tan, Xiaoli Ma, Yongxin Guo, et al.


  • Open Access

    Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies

    by Daijing Nie, Jing Zhang, Fang Wang, Wei Zhang, Lili Liu, Xue Chen, Yang Zhang, Panxiang Cao, Min Xiong, Tong Wang, et al.

    Background: Fanconi anemia (FA) is the most common inherited bone marrow failure (BMF) syndrome with 22 related genes identified. The ALDH2 rs671variant has been proved related to accelerate the progression of BMF in FA patients. The phenotype and genetic basis of Chinese FA patients have not been investigated yet.Methods: We analyzed the 22 FA-related genes of 63 BMF patients suspected to be FA. Clinical manifestations, morphological and cytogenetic feathers, ALDH2 genotypes, treatment, and outcomes of the definite cases were retrospectively studied.Results: A total of 21 patients were confirmed the diagnosis of FA with the median age of BMF onset was 4-year-old. The number of patients manifested as congenital malformations and growth retardation were 20/21 and 14/21, respectively. BM dysplasia and cytogenetic abnormalities were found in 13/20 and 8/19 patients. All the patients with abnormal karyotypes also manifested as BM dysplasia or had evident blasts. Thirty-five different mutations were identified involving six genes and including twenty novel mutations. FANCA mutations contributed to 66.67% of cases. Eight patients harboring ALDH2-G/A genotype have a significantly younger age of BMF onset (p=0.025). Within the 19 patients adhering to continuous follow-up, 15 patients underwent hematopoietic stem cell transplantations (HSCTs). During the 29 months of follow-up, 8/19 patients died, seven of which were HSCT-related, and one patient who did not receive HSCT died from severe infection.Conclusions: The phenotypic and genetic spectrum of Chinese FA patients is broad. Bone marrow dysplasia and cytogenetic abnormalities are prevalent and highly consistent. The overall outcome of HSCTs is disappointing. Nationwide multicenter studies are needed for the rarity and adverse outcome of this disease.

  • Open Access

    Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies

    by Daijing Nie, Jing Zhang, Fang Wang, Wei Zhang, Lili Liu, Xue Chen, Yang Zhang, Panxiang Cao, Min Xiong, Tong Wang, et al.

    Background: Fanconi anemia (FA) is the most common inherited bone marrow failure (BMF) syndrome with 22 related genes identified. The ALDH2 rs671variant has been proved related to accelerate the progression of BMF in FA patients. The phenotype and genetic basis of Chinese FA patients have not been investigated yet. Methods: We analyzed the 22 FA-related genes of 63 BMF patients suspected to be FA.Clinical manifestations, morphological and cytogenetic feathers, ALDH2 genotypes, treatment, and outcomes of the definite cases were retrospectively studied. Results: A total of 21 patients were confirmed the diagnosis of FA with the median age of BMF onset was 4-year-old. The number of patients manifested as congenital malformations and growth retardation were 20/21 and 14/21, respectively. BM dysplasia and cytogenetic abnormalities were found in 13/20 and 8/19 patients. All the patients with abnormal karyotypes also manifested as BM dysplasia or had evident blasts. Thirty-five different mutations were identified involving six genes and including twenty novel mutations. FANCA mutations contributed to 66.67% of cases. Eight patients harboring ALDH2 -G/A genotype have a significantly younger age of BMF onset ( p =0.025). Within the 19 patients adhering to continuous follow-up, 15 patients underwent hematopoietic stem cell transplantations (HSCTs). During the 29 months of follow-up, 8/19 patients died, seven of which were HSCT-related, and one patient who did not receive HSCT died from severe infection. Conclusion: The phenotypic and genetic spectrum of Chinese FA patients is broad. Bone marrow dysplasia and cytogenetic abnormalities are prevalent and highly consistent. The overall outcome of HSCTs is disappointing. Nationwide multicenter studies are needed for the rarity and adverse outcome of this disease.

  • Open Access

    Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies

    by Daijing Nie, Jing Zhang, Fang Wang, Wei Zhang, Lili Liu, Xue Chen, Yang Zhang, Panxiang Cao, Min Xiong, Tong Wang, et al.

    Background: Fanconi anemia (FA) is the most common inherited bone marrow failure (BMF) syndrome with 22 related genes identified. The ALDH2 rs671variant has been proved related to accelerate the progression of BMF in FA patients. The phenotype and genetic basis of Chinese FA patients have not been investigated yet. Methods: We analyzed the 22 FA-related genes of 63 BMF patients suspected to be FA.Clinical manifestations, morphological and cytogenetic feathers, ALDH2 genotypes, treatment, and outcomes of the definite cases were retrospectively studied. Results: A total of 21 patients were confirmed the diagnosis of FA with the median age of BMF onset was 4-year-old. The number of patients manifested as congenital malformations and growth retardation were 20/21 and 14/21, respectively. BM dysplasia and cytogenetic abnormalities were found in 13/20 and 8/19 patients. All the patients with abnormal karyotypes also manifested as BM dysplasia or had evident blasts. Thirty-five different mutations were identified involving six genes and including twenty novel mutations. FANCA mutations contributed to 66.67% of cases. Eight patients harboring ALDH2 -G/A genotype have a significantly younger age of BMF onset ( p =0.025). Within the 19 patients adhering to continuous follow-up, 15 patients underwent hematopoietic stem cell transplantations (HSCTs). During the 29 months of follow-up, 8/19 patients died, seven of which were HSCT-related, and one patient who did not receive HSCT died from severe infection. Conclusion: The phenotypic and genetic spectrum of Chinese FA patients is broad. Bone marrow dysplasia and cytogenetic abnormalities are prevalent and highly consistent. The overall outcome of HSCTs is disappointing. Nationwide multicenter studies are needed for the rarity and adverse outcome of this disease.